Accordingly, with these findings, GW9662 treatment in association with SP showed a low ability to resolve GBM histopathological characteristics, consistent with previous studies where PPAR-γ antagonists reversed the protective effects of PPAR-γ agonists [63,64]. This evidence concerns the gene PPARG and glioblastoma.